norethindrone acetate has been researched along with Bone Loss, Osteoclastic in 9 studies
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether add-back therapy with norethindrone acetate or norethindrone acetate plus conjugated equine estrogens is superior to maintain bone health in adolescents and young women using gonadotropin-releasing hormone agonists for endometriosis." | 5.20 | Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial. ( DiVasta, AD; Feldman, HA; Gordon, CM; Hornstein, MD; Laufer, MR; Sadler Gallagher, J; Stokes, NA, 2015) |
| " We thus performed a randomized, double-blind, placebo-controlled intervention study to prospectively investigate the effect of a low dose of fluoride, in combination with HRT, on BMD and biochemical markers of bone turnover." | 2.69 | Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. ( Alexandersen, P; Christiansen, C; Riis, BJ, 1999) |
| "In conclusion, bone resorption is suppressed in the luteal phase through a mechanism that does not involve increases in serum OPG." | 1.32 | Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. ( Abrahamsen, B; Beck-Nielsen, H; Bonnevie-Nielsen, V; Rettmer, E; Stilgren, LS, 2003) |
| "Reflecting an increase in bone resorption, 3H-T levels in tibiae and vertebrae were decreased in placebo-treated OVX animals compared to the placebo-treated SO group (p < 0." | 1.29 | High-dose gestagens modulate bone resorption and formation and enhance estrogen-induced endosteal bone formation in the ovariectomized mouse. ( Bailey, MC; Bain, SD; Celino, DL; Edwards, MW; Jensen, E; Lantry, MM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Costa-Paiva, L | 1 |
| O Wender, MC | 1 |
| Machado, RB | 1 |
| Pompei, LM | 1 |
| Nahas, EA | 1 |
| Nahas-Neto, J | 1 |
| Del Debbio, SY | 1 |
| Badalotti, M | 1 |
| Cruz, AM | 1 |
| DiVasta, AD | 1 |
| Feldman, HA | 1 |
| Sadler Gallagher, J | 1 |
| Stokes, NA | 1 |
| Laufer, MR | 1 |
| Hornstein, MD | 1 |
| Gordon, CM | 1 |
| Pullerits, R | 1 |
| d'Elia, HF | 1 |
| Tarkowski, A | 1 |
| Carlsten, H | 1 |
| Abrahamsen, B | 1 |
| Stilgren, LS | 1 |
| Rettmer, E | 1 |
| Bonnevie-Nielsen, V | 1 |
| Beck-Nielsen, H | 1 |
| Crisafulli, A | 1 |
| Altavilla, D | 1 |
| Squadrito, G | 1 |
| Romeo, A | 1 |
| Adamo, EB | 1 |
| Marini, R | 1 |
| Inferrera, MA | 1 |
| Marini, H | 1 |
| Bitto, A | 1 |
| D'Anna, R | 1 |
| Corrado, F | 1 |
| Bartolone, S | 1 |
| Frisina, N | 1 |
| Squadrito, F | 1 |
| Bain, SD | 1 |
| Jensen, E | 1 |
| Celino, DL | 1 |
| Bailey, MC | 1 |
| Lantry, MM | 1 |
| Edwards, MW | 1 |
| Alexandersen, P | 1 |
| Riis, BJ | 1 |
| Christiansen, C | 1 |
| Bernard-Poenaru, O | 1 |
| Roux, C | 1 |
| Blanqué, R | 1 |
| Gardner, C | 1 |
| de Vemejoul, MC | 1 |
| Cohen-Solal, ME | 1 |
| Karambolova, KK | 1 |
| Snow, GR | 1 |
| Anderson, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial[NCT00474851] | Phase 2 | 53 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Genistein Use in Postmenopausal Women With Metabolic Syndrome[NCT00541710] | Phase 2/Phase 3 | 120 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adjusted mean change in total body areal bone mineral density (aBMD) over the 12 month trial (NCT00474851)
Timeframe: Baseline to 12 months
| Intervention | g/cm^2 (Mean) |
|---|---|
| Intervention Group | 0.01 |
| Placebo Group | -0.11 |
(NCT00474851)
Timeframe: Baseline to 12 months
| Intervention | g (Mean) |
|---|---|
| Intervention Group | 37 |
| Placebo Group | 15 |
6 trials available for norethindrone acetate and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effects of ultra-low dose hormone therapy on biochemical bone turnover markers in postmenopausal women: A randomized, placebo-controlled, double-blind trial.
Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Collagen Type I; D | 2022 |
Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
Topics: Absorptiometry, Photon; Adolescent; Bone Density; Bone Resorption; Dose-Response Relationship, Drug; | 2015 |
The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial.
Topics: Alkaline Phosphatase; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Density; Bone Resorpti | 2009 |
Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
Topics: Amino Acids; Bone Density; Bone Remodeling; Bone Resorption; Carrier Proteins; Double-Blind Method; | 2004 |
Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
Topics: Aged; Bone Density; Bone Remodeling; Bone Resorption; Calcium; Double-Blind Method; Drug Synergism; | 1999 |
Bone-resorbing cytokines from peripheral blood mononuclear cells after hormone replacement therapy: a longitudinal study.
Topics: Aged; Amino Acids; Bone Resorption; Cells, Cultured; Cytokines; Estradiol; Estrogen Replacement Ther | 2001 |
3 other studies available for norethindrone acetate and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6.
Topics: Adolescent; Adult; Aged; Bone Resorption; Cells, Cultured; Estradiol; Estrogen Replacement Therapy; | 2003 |
High-dose gestagens modulate bone resorption and formation and enhance estrogen-induced endosteal bone formation in the ovariectomized mouse.
Topics: Analysis of Variance; Animals; Bone Development; Bone Resorption; Estradiol; Female; Femur; Megestro | 1993 |
Surface activity on the periosteal and corticoendosteal envelopes following continuous progestogen supplementation in spayed beagles.
Topics: Animals; Bone and Bones; Bone Resorption; Dogs; Female; Minerals; Norethindrone; Norethindrone Aceta | 1986 |